BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35100718)

  • 1. Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma.
    Roderwieser A; Sand F; Walter E; Fischer J; Gecht J; Bartenhagen C; Ackermann S; Otte F; Welte A; Kahlert Y; Lieberz D; Hertwig F; Reinhardt HC; Simon T; Peifer M; Ortmann M; Büttner R; Hero B; O'Sullivan RJ; Berthold F; Fischer M
    JCO Precis Oncol; 2019 Dec; 3():1-20. PubMed ID: 35100718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic strategies targeting telomere maintenance mechanisms in high-risk neuroblastoma.
    George SL; Parmar V; Lorenzi F; Marshall LV; Jamin Y; Poon E; Angelini P; Chesler L
    J Exp Clin Cancer Res; 2020 May; 39(1):78. PubMed ID: 32375866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR.
    Zhao M; Guan Z; Gong L; Liu F; Gu W; Liu L; Jiang K; Cai J; Feng C; Kuick CH; Chang KTE; Wang J; Tang H; Yin M; Mao J
    Pathology; 2023 Dec; 55(7):958-965. PubMed ID: 37741703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere biology including TERT rearrangements in neuroblastoma: a useful indicator for surgical treatments.
    Kawashima M; Kojima M; Ueda Y; Kurihara S; Hiyama E
    J Pediatr Surg; 2016 Dec; 51(12):2080-2085. PubMed ID: 27793328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
    Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
    Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
    Peifer M; Hertwig F; Roels F; Dreidax D; Gartlgruber M; Menon R; Krämer A; Roncaioli JL; Sand F; Heuckmann JM; Ikram F; Schmidt R; Ackermann S; Engesser A; Kahlert Y; Vogel W; Altmüller J; Nürnberg P; Thierry-Mieg J; Thierry-Mieg D; Mariappan A; Heynck S; Mariotti E; Henrich KO; Gloeckner C; Bosco G; Leuschner I; Schweiger MR; Savelyeva L; Watkins SC; Shao C; Bell E; Höfer T; Achter V; Lang U; Theissen J; Volland R; Saadati M; Eggert A; de Wilde B; Berthold F; Peng Z; Zhao C; Shi L; Ortmann M; Büttner R; Perner S; Hero B; Schramm A; Schulte JH; Herrmann C; O'Sullivan RJ; Westermann F; Thomas RK; Fischer M
    Nature; 2015 Oct; 526(7575):700-4. PubMed ID: 26466568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliable assessment of telomere maintenance mechanisms in neuroblastoma.
    Meeser A; Bartenhagen C; Werr L; Hellmann AM; Kahlert Y; Hemstedt N; Nürnberg P; Altmüller J; Ackermann S; Hero B; Simon T; Peifer M; Fischer M; Rosswog C
    Cell Biosci; 2022 Sep; 12(1):160. PubMed ID: 36153564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promotor region rearrangements analyzed in high-risk neuroblastomas by FISH method and whole genome sequencing.
    Kawashima M; Ueda Y; Kurihara S; Hiyama E
    Int J Clin Oncol; 2020 Dec; 25(12):2166-2174. PubMed ID: 32894394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma?
    Akter J; Kamijo T
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.
    Lundberg G; Sehic D; Länsberg JK; Øra I; Frigyesi A; Castel V; Navarro S; Piqueras M; Martinsson T; Noguera R; Gisselsson D
    Genes Chromosomes Cancer; 2011 Apr; 50(4):250-62. PubMed ID: 21319260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
    Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
    Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
    Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
    J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
    Farooqi AS; Dagg RA; Choi LM; Shay JW; Reynolds CP; Lau LM
    J Neurooncol; 2014 Aug; 119(1):17-26. PubMed ID: 24792489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.
    Nakazawa A
    Pathol Int; 2021 Apr; 71(4):232-244. PubMed ID: 33657257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.
    Duan XF; Zhao Q
    J Pediatr Hematol Oncol; 2018 Jan; 40(1):1-6. PubMed ID: 28452859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational practice of fluorescence in situ hybridisation to identify neuroblastic tumours with TERT rearrangements.
    Yu Y; Zhang M; Yao X; Guan X; Jia C; Chu P; Zhang R; Yang Y; Jin Y; Wang H; Ni X; He L; Guo Y
    J Pathol Clin Res; 2023 Nov; 9(6):475-487. PubMed ID: 37608330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
    Onitake Y; Hiyama E; Kamei N; Yamaoka H; Sueda T; Hiyama K
    J Pediatr Surg; 2009 Dec; 44(12):2258-66. PubMed ID: 20006006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors.
    Valentijn LJ; Koster J; Zwijnenburg DA; Hasselt NE; van Sluis P; Volckmann R; van Noesel MM; George RE; Tytgat GA; Molenaar JJ; Versteeg R
    Nat Genet; 2015 Dec; 47(12):1411-4. PubMed ID: 26523776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.